Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.4 HKD | -5.29% | +10.67% | -19.76% |
04-30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
04-29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.76% | 1.4B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%